At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 244 enrolled
Drug / intervention
TVP-1012 +1 moredrug
Likely dose
TVP-1012 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa
In Brief
A Phase 3 clinical trial evaluating TVP-1012 and Placebo for Parkinson's Disease. Completed, enrolled 244 participants across 55 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedJan 14, 2015
Enrollment StartFeb 7, 2015
Primary CompletionSep 15, 2016
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 11.5 years ago
Interventions
TVP-1012drug
TVP-1012 1mg Tablets
Placebodrug
Placebo tablets